Polio returns to the USA: An epidemiological alert

Anushree Rai, Olivier Uwishema, Lama Uweis, Rayyan El Saleh, Sara Arab, Mortada Abbass, Jack Wellington, Felix Musabirema, Irem Adanur, Chinyere Vivian Patrick Onyeaka

PII: S2049-0801(22)01323-1
DOI: https://doi.org/10.1016/j.amsu.2022.104563
Reference: AMSU 104563

To appear in: Annals of Medicine and Surgery

Received Date: 26 August 2022
Revised Date: 27 August 2022
Accepted Date: 28 August 2022


This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd.
Polio returns to the USA: An Epidemiological Alert

Anushree Rai\textsuperscript{1,5}; Olivier Uwishema\textsuperscript{1,2,3*}; Lama Uweis\textsuperscript{1,4}; Rayyan El Saleh\textsuperscript{1,4}; Sara Arab\textsuperscript{1,4}; Mortada Abbass\textsuperscript{1,4}; Jack Wellington MSc (LSHTM) FGMS \textsuperscript{1,6}; Felix Musabirema\textsuperscript{7}; Irem Adanur\textsuperscript{1,3}; Chinyere Vivian Patrick Onyeaka\textsuperscript{8}

1. Oli Health Magazine Organization, Research and Education, Kigali, Rwanda
2. Clinton Global Initiative University, New York, USA
3. Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey.
4. Faculty of Medicine, Beirut Arab University, Beirut, Lebanon.
5. Chhattisgarh institute of Medical sciences, Bilaspur, Chhattisgarh, India
6. Faculty of Medicine, Cardiff University School of Medicine, Cardiff University, Cardiff, UK
7. Clinical Research physician at Rwanda Zambia Health Research Group (RZHRG), Kigali, Rwanda
8. Department of Emergency Medicine, Watford General Hospital, West Hertfordshire Teaching Hospitals NHS Trust, Watford, United Kingdom

*Corresponding Author –
Olivier Uwishema\textsuperscript{1,2,3*}
Oli Health Magazine Organization, Research and Education
Kigali, Rwanda
Email: uwolivier1@ktu.edu.tr \textsuperscript{1,2,3*}
Tel: +905061545340
ORCID ID: https://orcid.org/0000-0002-0692-9027
AUTHORS’ CONTRIBUTION

Olivier Uwishema: Conceptualization, Project administration, Writing-review and Designing

Mortada Abbass: Collection and assembly of data

Olivier Uwishema: Reviewed and edited the first draft, supervisor

Jack Wellington MSc (LSHTM) FGMS: Reviewed and edited the second draft.

Chinyere Vivian Patrick Onyeaka: Reviewed and edited the final draft, Supervisor

Manuscript writing: All authors

Final approval of manuscript: All authors

Figure 3: Strategies for Polio eradication was drawn and analyzed by authors Anushree Rai$^{1,5}$ and Olivier Uwishema$^{1,2,3,*}$

Figure 4 summarizing polio in the USA and suggested recommendations was drawn and analyzed by authors Anushree Rai$^{1,5}$ and Olivier Uwishema$^{1,2,3,*}$
Polio returns to the USA: An Epidemiological Alert

Abstract:
On 21st July 2022, the USA witnessed the first case of poliomyelitis after 3 decades of its eradication. Poliomyelitis is a crippling disease that results from infection with any one of the three related poliovirus types (referred to as types P1, P2, and P3), members of the enterovirus (picornavirus) family. The New York State Department of Health confirmed that a case of paralytic poliomyelitis was reported from a 20-year-old Hungarian traveler residing in Rockland County. The detected viral sequence has been found to have vaccine-derived poliovirus type 2 (VDPV2) suggesting an origin from the live attenuated oral polio vaccine (OPV). Since immunisation remains the only preventable measure, this article explores suggestions from the Centers for Disease Control and Prevention on reliable Inactivated (killed) polio vaccination in high-risk patients along with early case detection and treatment. In light of the above-mentioned findings, this research further details future recommendations like cessation of the OPV, encouragement of inactivated polio vaccine (IPV) in vaccination schedules, sensitive epidemiological surveillance system and appropriate training for healthcare providers. The affected countries have been further advised to have effective outbreak response strategy plans in place so that they can respond and stay prepared for such outbreaks in the future.

Keywords: Polio, United States of America, OPV, VDPV2, VAPP, USA

Introduction:
Poliomyelitis is an incurable and serious infectious disease caused by poliovirus\(^1\). It can cause acute muscle paralysis, permanent central nervous system damage, and even death\(^2\). As per the World Health Organization (WHO), death occurs in about 5-10% of patients who become permanently paralyzed due to immobilization of their breathing muscles\(^3\). The human gastrointestinal tract is considered the foremost reservoir of the infection; the route of transmission is oral-oral and/or oral-fecal\(^4\). Patients are considered highly infectious during a period of seven to ten days before and after the first day of symptoms\(^4\). However, the infection continues to be spread for up to two or three weeks through feces\(^3\). The virus can be detected in stools for five weeks or in the nasopharynx for five days after the first onset of symptoms\(^4\). Initial symptoms could be fever, headache, nausea, fatigue, vomiting, pain, and stiffness of the neck\(^3\). According to the CDC, there are three different types of wild polio; type 1, 2, and 3\(^5\). Because polio still has no available cure, prevention remains the key. Prevention is being successfully achieved through the two available vaccines (oral polio vaccine and inactivated polio vaccine) which are both effective and safe\(^3\). Moreover, after launching the Global Polio Eradication Initiative (GPEI) in 1988, WHO reports that poliomyelitis cases have decreased from
350,000 in the year 1988 to only 6 confirmed cases in the year 2021\(^3\). The first polio outbreak in the United States of America (USA) was in the late 1940s\(^6\). Poliovirus disease reached its highest incidence in the USA in the year 1952 with a total number of 20,000 paralytic polio cases\(^7\). The last polio case in the USA was in 1993 which was brought to the country by travelers\(^6\). Surprisingly, the CDC confirmed on July 21\(^{st}\), 2022, a new case of polio in Rockland County, New York\(^6\). The patient was not previously vaccinated and the public health workers in the state are working to know how was this man infected\(^6\).

**Epidemiology and outbreak of Polio in the USA:**

Wild poliovirus was eradicated from the USA 30 years ago and since then no case has been detected originally as a wild virus from USA citizens according to CDC\(^8\). However, multiple cases were detected known to be brought by travellers carrying the virus\(^8\). The first outbreak, the USA witnessed was in the late 1940s harbouring the lives of thousands of USA citizens yet the number significantly decreased beyond the year 1955 after the introduction of inactivated Polio vaccine\(^9\). Since late 1979, no case of wild-type poliomyelitis was detected in the USA and until the year 1999, only 162 cases were identified with a rate of 6 cases per year\(^9\). Most of the mentioned cases in that era were vaccine-associated paralytic poliomyelitis (VAPP) derived from the Sabin strain found in the oral poliovirus vaccine (OPV)\(^9\). Despite the efforts placed to eradicate this disease from the USA entirely, especially after declining the OPV to decrease the VAPP. Surprisingly on 21 July 2022, a case of paralytic poliomyelitis in an unvaccinated traveller residing in Rockland County was reported to the New York State Department of Health\(^10\). According to the USA CDC, sequencing of the virus from the detected case is VDPV2 vaccine-derived poliovirus type 2 and this might suggest that the virus affecting the 20-year aged man travelling from Hungary might be from an OPV\(^10\). It appears that the rates of polio vaccination in the USA have declined in recent years and even before the novel coronavirus disease 2019 (COVID-19) pandemic to below 95% coverage and with the burdens, the COVID-19 pandemic has thrown on the healthcare service it seems that the vaccination rates are in decline threatening in a potential outbreak, especially after the arrival of a wild or even VAPP\(^10,11\) (See figure 1) and (Figure 2). Therefore, the CDC has advised people to vaccinate their children and high-risk population to overcome the high-risk situation and maintain enough herd immunity\(^8,11\).
Figure 1: Level of reported cases of paralytic polio from vaccine-derived viruses between 2016-2021. [12]

![Graph showing reported cases of paralytic polio from vaccine-derived viruses from 2016 to 2021.](image)

162 confirmed cases of paralytic poliomyelitis were reported in the United States between 1980–1999

![Pie chart showing the distribution of confirmed polio cases in the USA between 1980 and 1999.](image)

Figure 2: A chart explaining the origin of confirmed polio cases in the USA between the years 1980 and 1999. (drawn by the author)

Aetiology of Polio:

Poliovirus was discovered in wastewater samples collected from two distinct locations in Orange County in June and July, according to the New York State Department of Health\textsuperscript{13}. The results follow the paralysis and hospitalization of an adult who was not immunized with polio in Rockland County last month\textsuperscript{13}. According to the CDC, there have been no new cases of polio in the USA since 1979\textsuperscript{13}. The United States has not officially confirmed an infection since 2013 until the case in Rockland County\textsuperscript{13}. The case in Rockland County contracted a strain of polio from the OPV, which shows that the line of transmission did not start in the USA\textsuperscript{13}. The OPV contains a weak variant of the virus that can still multiply\textsuperscript{13}. Therefore, those who take the OPV are at risk of transmitting the virus to others\textsuperscript{13}. However, the OPV hasn’t been used in the USA in over 20 years\textsuperscript{13}. People who receive the inactivated polio shot cannot spread the illness to others because the vaccination employs a virus strain that cannot replicate\textsuperscript{13}. Moreover, the case in New York has been genetically related, according to Global Polio Laboratory Network (GPLN), to two isolates of Sabin-like type 2 (SL2) that were found in early June.
samples from Rockland County, as well as to the recently discovered VDPV2 found in environmental samples from London, UK\textsuperscript{14}. New Yorkers need to understand that this does not indicate that the specific case discovered in New York has a history of travel to the UK\textsuperscript{14}.

Note that polio is a highly contagious disease that spreads from person to person; a person can spread the virus even if they are healthy\textsuperscript{14}. Polio can enter the USA with just one traveller carrying the illness\textsuperscript{6}. Those most susceptible to infection include the non-vaccinated for polio, those who didn't complete the recommended number of vaccinations and those going to places where they might be in danger of contracting polio\textsuperscript{6}.

**Current efforts to Mitigate Polio in the USA:**

July 21, 2022: The CDC is working with the New York State Department of Health on their investigation into a case of polio in an unvaccinated person from Rockland County, New York\textsuperscript{6}. To stop the spread of polio to people who haven't received the recommended vaccinations or who haven't received them at all, public health professionals are working to determine how and where the person became ill\textsuperscript{6}. They are also offering the community protective measures like vaccination services\textsuperscript{6}. Polio has no known treatment, but it can be avoided with a reliable immunization\textsuperscript{6}. The wild poliovirus has been eradicated in this nation for more than 30 years thanks to the polio vaccine, committed medical experts, and vigilant parents who vaccinate their children on time\textsuperscript{6}. This indicates that the wild poliovirus is not continuously transmitted throughout the year in the USA\textsuperscript{6}. Maintaining strong immunity (protection) against polio in the population through vaccination is the greatest strategy to keep individuals safe from the disease\textsuperscript{6} (See Figure 3). In Rockland County, samples from June were found to have the polio virus, according to an examination from the CDC\textsuperscript{6}.

New York wastewater samples are shared with the GPLN, which consists of the CDC and the World Health Organization (WHO), as part of continuous surveillance activities\textsuperscript{14}. All unvaccinated residents of New York, especially those who are pregnant, 2 months of age or older, and those who have not finished their previous polio vaccination series, should get immunized right away\textsuperscript{14}. The largest risk of exposure is among unvaccinated New Yorkers who reside in Rockland County, work there, attend school there, or travel there\textsuperscript{14}. Polio has no known cure or treatment, but it can be avoided with a reliable immunization\textsuperscript{14}. 
Recommendations:

Amid the COVID-19 pandemic which has affected healthcare services globally, routine polio vaccination rates have continued to decline. Therefore efforts to achieve and maintain high rates of polio vaccination coverage (>95%) within the population effective advocating high and homogeneous vaccination coverage programs is highly emphasized. This can be achieved by strengthening routine administration of inactivated polio vaccines (IPV) to children under 15 years located in high-risk areas, this is a powerful preventive measure and has been a key achievement strategy for eliminating polio cases.
in the past 30 years of polio-free in the USA\textsuperscript{16}. Improving polio cases detection and disease response through a sensitive epidemiological surveillance system will allow timely detection and investigation of acute flaccid paralysis (AFP) which is a presenting feature of poliomyelitis cases among children who are under 15 years in high-risk population\textsuperscript{19}. It can only be possible if direct detection using modern laboratory with new technologies and tools for poliovirus detection and characterization, but also training healthcare workers at all levels to employ modern techniques in detection and case notification will be important in sample tracking and transportation by targeting geographical areas with the most pronounced delays\textsuperscript{15,30-36}. To stop all cases of paralytic poliomyelitis due to VDPV2, we highly recommend the cessation of the OPV and encourage IPV use in the vaccination program schedules\textsuperscript{16}. Effective implementation of this policy will prevent polio cases due to OPV uses among children, since the current epidemiological alert is like to OPV\textsuperscript{16}. As far as poliomyelitis epidemiological alert is concerned, countries and member states are advised to have outbreak response strategic plans in place so that to be prepared to respond in a timely fashion to the occurrence of an imported wild poliovirus (WPV) or vaccine-derived poliovirus case or the emergence of VDPV2 in their counties\textsuperscript{17}. These recommendations can be applied in other countries especially the low and middle-income countries as a preparatory strategy to respond immediately to poliomyelitis cases in the future\textsuperscript{21-29} (See Figure 4).
Conclusion:

On 21st July 2022, the USA witnessed the first case of poliomyelitis after nearly 3 decades of its eradication. Despite the efforts to prevent any further outbreaks, a case of paralytic poliomyelitis in a traveller residing in Rockland County was reported to the New York State Department of Health. According to the US CDC, the detected sequence has been found to have VDPV2 vaccine-derived poliovirus type 2 and this might suggest that the origin of the virus affecting the 20-year aged man travelling from Hungary might be from the OPV. Since poliomyelitis is a highly contagious disease with no available cure, prevention remains the key. As a result, the
CDC has recommended reliable immunisation to all New York residents especially those who are pregnant, 2 months of age or older, and those who have not finished their previous polio vaccination series. Wastewater samples were also shared with GPLN consisting of CDC and WHO as part of continuous surveillance activities. In response to the current situation, we highly recommend the cessation of OPV and encourage IPV use in the vaccination program schedules. Improving polio cases detection and disease response through a sensitive epidemiological surveillance system will allow timely detection and investigation of AFP due to poliomyelitis. Appropriate training for healthcare providers to employ modern techniques in detection and sample collection is necessary to tackle cases in challenging geographical areas. Lastly, we strongly advise the affected countries including low and middle-tier countries, to have effective outbreak response strategy plans in place so that they can respond and stay prepared for such outbreaks in the future.

REFERENCES:


9. F. Estivariz, MD; Ruth Link-Gelles, PhD, MPH; and Tom Shimabukuro, MD, MPH, MBA(August 18, 2021). Available at: https://www.cdc.gov/vaccines/pubs/pinkbook/polio.html#:~:text=From%20the%20more%20than%2021%20000,communities%20in%20several%20Midwestern%20states.


The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.

Please state any conflicts of interest
All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

No conflicts of interest declared.

Please state any sources of funding for your research
All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.

None.

Ethical Approval
Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement.

Not Applicable.
Consent
Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.

Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: “Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request”.

Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions.

Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.

Not Applicable.

Author contribution
Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors.

| Olivier Uwishema: Conceptualization, Project administration, Writing-review and Designing |
| Mortada Abbass: Collection and assembly of data |
| Olivier Uwishema: Reviewed and edited the first draft, supervisor |
| Jack Wellington MSc (LSHTM) FGMS: Reviewed and edited the second draft. |
| Chinyere Vivian Patrick Onyeaka: Reviewed and edited the final draft, Supervisor |
| Manuscript writing: All authors |
Final approval of manuscript: All authors

**Figure 3:** Strategies for Polio eradication was drawn and analyzed by authors Anushree Rai\(^1,5\) and Olivier Uwishema\(^{1,2,3}\)*

**Figure 4** summarizing polio in the USA and suggested recommendations was drawn and analyzed by authors Anushree Rai\(^1,5\) and Olivier Uwishema\(^{1,2,3}\)*

Registration of Research Studies

In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study.

You can register any type of research at [http://www.researchregistry.com](http://www.researchregistry.com) to obtain your UIN if you have not already registered. This is mandatory for human studies only. Trials and certain observational research can also be registered elsewhere such as: ClinicalTrials.gov or ISRCTN or numerous other registries.

1. Name of the registry: **Not Applicable**

2. Unique Identifying number or registration ID: **Not Applicable**

3. Hyperlink to your specific registration (must be publicly accessible and will be checked): **Not Applicable**

Guarantor

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish
Olivier Uwishema; Principal Investigator (PI)